HIGHLIGHTS
- who: Carcinoma Where Do We and collaborators from the Department of Radiation Oncology, University of, Germany have published the research work: Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell to Go?, in the Journal: (JOURNAL)
- what: The aim is to test the effect of local RT on systemic response to pembrolizumab. In the peri-operative setting, the French NIVOPOSTOP trial aims to evaluate the benefit of adding nivolumab to CRT for patients with LA-SCCHN and ECOG PS 0-1, who receive postoperative CRT for R1 resection or extracapsular extension (ECE . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.